Abiopharma

🔍 Burrows Scott L (Executive)

Company: Spyre Therapeutics, Inc. (SYRE)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 12,500 shares of Common Stock at $14.5 per share (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 110,494.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 12,500 shares of Common Stock at $71.37 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 97,994.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 12,500 shares of Stock Option (Right to Buy) at $14.5 per share (Derivative)
  Date: 2026-05-01 | Code: M | Expires: 2033-09-01 | equity_swap_involved: 0 | shares_owned_after: 382,357.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
• F2: Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.
• F3: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.